Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.
Clinical trials
Correlatives
Mesothelioma
Pathologic classification
Pathology
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
05
02
2019
revised:
20
06
2019
accepted:
20
06
2019
pubmed:
2
7
2019
medline:
17
7
2020
entrez:
2
7
2019
Statut:
ppublish
Résumé
The accurate diagnosis of mesothelioma is critical for the appropriate clinical management of this cancer. Many issues complicate making the diagnosis of mesothelioma including the presence of reactive mesothelial cells in benign pleural effusions, the heterogeneity of mesothelioma histopathology, the relatively high incidence of other epithelial malignancies that metastasize to the pleura, and primary sarcomas that arise within the pleura. Given the rapidly evolving field of molecular profiling and the need for translational correlates in mesothelioma clinical trials, the National Cancer Institute (NCI)-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting was convened in March 2017 to develop a consensus on standard pathology guidelines for future NCI-sponsored clinical trials in mesothelioma. This consensus statement covers recommendations for specimen handling, pathologic classification and diagnosis, biobanking, and tissue correlative studies.
Identifiants
pubmed: 31260832
pii: S1556-0864(19)30502-7
doi: 10.1016/j.jtho.2019.06.020
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1704-1717Informations de copyright
Copyright © 2019 International Association for the Study of Lung Cancer. All rights reserved.